AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22699838
Drug: Senna (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senna (15 mL daily for ages 6-12 or 30 mL daily for ages 12-21 for 2 days)
Trial: 21362056
Drug: Concurrent strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent strength and endurance (SE) training
Trial: 19563006
Drug: Perioperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative administration of celecoxib (200 mg twice daily, starting 3 days before TKA and extending to 5 days postoperatively)
Trial: 19563006
Drug: Perioperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative administration of celecoxib
Trial: 19563006
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (postoperative administration of celecoxib, 200 mg twice daily, starting 2 hours after TKA and extending to 5 days postoperatively)
Trial: 15546434
Drug: Low-fat plant
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat plant sterol ester (PSE)‐enriched spread (21 g day(‐1))
Trial: 11342469
Drug: Magnetic Resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic Resonance (MR) using gadolinium-diethylenetriamine pentaacetic acid bismethylamide (Omniscan; 0.1 mmol/kg injected at 3 mL/s IV) during hyperemia (dipyridamole 0.56 mg/kg)
Trial: 9246252
Drug: Treatment focusing
RxNorm normalized name: ficusin
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment focusing on sexual dysfunction
Trial: 9246252
Drug: Treatment focusing
RxNorm normalized name: ficusin
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment focusing on interpersonal problems
Trial: 9246252
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both sexual dysfunction and interpersonal problems
Trial: 3518552
Drug: Protocol I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol I (0 mg fentanyl)
Trial: 3518552
Drug: Protocol II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol II (0.05 mg fentanyl)
Trial: 3518552
Drug: Protocol III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol III (0.1 mg fentanyl)
Trial: 3518552
Drug: Protocol IV
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol IV (0.15 mg fentanyl)
Trial: 24630745
Drug: Interdisciplinary occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary occupational and sport therapy intervention for dementia patients suffering from apathy, provided once a week for 10 months.
Trial: 12652617
Drug: all-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all-trans-retinoic acid (ATRA) at a dosage of 25 mg/m(2)/day
Trial: 10853849
Drug: 1,250 mg
RxNorm normalized name: garlic 1,250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,250 mg azithromycin
Trial: 1991527
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive (OC, 7‐7‐7)
Trial: 1991527
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to monophasic pill (1/35)
Trial: 1991527
Drug: 0.5/35 monophasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5/35 monophasic pill
Trial: 1991527
Drug: 1/35 monophasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/35 monophasic pill
Trial: 6826814
Drug: Cephalexin (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (twice daily)
Trial: 6826814
Drug: Dicloxacillin (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicloxacillin (four times daily)
Trial: 26818376
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (one stick of sugarless gum during the pause interval of drinking polyethylene glycol solution)
Trial: 26818376
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drank polyethylene glycol solution according to the general protocol)
Trial: 25066331
Drug: Hydrocortisone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (200 mg per day tapered) and fludrocortisone (50 μg tablet once per day)
Trial: 23202523
Drug: HAI-05 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI-05 vaccine (15, 45, and 90 µg) with Alhydrogel® (0.75 mg aluminum per dose)
Trial: 23202523
Drug: HAI-05 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI-05 vaccine (90 µg) without Alhydrogel®
Trial: 20214068
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Estazolam
Trial: 12404512
Drug: Cerebrospinal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrospinal fluid (CSF) from MS patients with 0.1 mM ITU (specific iNOS inhibitor)
Trial: 12404512
Drug: Cerebrospinal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrospinal fluid (CSF) from MS patients with 1 mM L-NMMA (nonisoform specific NOS inhibitor)
Trial: 354826
Drug: L-alpha-methyldopa hydrazine
RxNorm normalized name: L-alpha-Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-alpha-methyldopa hydrazine
Trial: 31340316
Drug: Strength program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength program with TheraBands® for 12 weeks, with two weekly sessions
Trial: 22981376
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (2 hours weekly for six months)
Trial: 22981376
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (control for patients)
Trial: 12943436
Drug: Active infant
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active infant orthopedic treatment with Latham dentomaxillary alignment (DMA) appliance inserted at 5 to 6 weeks of age.
Trial: 12943436
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active infant orthopedic treatment (nonorthopedic group).
Trial: 11711509
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 mg per day)
Trial: 11711509
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg per day)
Trial: 9164679
Drug: Primary medical
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary medical therapy (PMT)
Trial: 18230798
Drug: Adjuvant chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoendocrine therapy
Trial: 8047746
Drug: Surrogate information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surrogate information time for monitoring treatment effects
Trial: 3310870
Drug: alpha‐2a interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐2a interferon at 30 X 10(6) IU/ml
Trial: 3310870
Drug: alpha‐2a interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐2a interferon at 10 X 10(6) IU/ml
Trial: 2100737
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aqueous extract (Group A)
Trial: 2100737
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg standardized extract (Group C)
Trial: 25543971
Drug: Diltiazem 360
RxNorm normalized name: dilTIAZem 360 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 360 mg/day (or 5 mg/kg/day)
Trial: 23953594
Drug: 200 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg/day of vitamin K1
Trial: 17374063
Drug: Topical high-potency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical high-potency corticosteroid before UVB exposure
Trial: 12638566
Drug: Rocuronium 1
RxNorm normalized name: rocuronium 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 1 mg x kg(‐1)
Trial: 12638566
Drug: Pancuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.1 mg x kg(‐1)
Trial: 1796130
Drug: Methylphenidate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.5 mg/kg infusion
Trial: 1796130
Drug: Neuroleptics (on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptics (on treatment)
Trial: 1796130
Drug: Neuroleptics (off
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptics (off treatment)
Trial: 29167092
Drug: Dry needling,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling, manual therapy, and exercise
Trial: 29167092
Drug: Sham dry
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham dry needling, manual therapy, and exercise
Trial: 31825525
Drug: Abdominal paracentesis
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal paracentesis and intraperitoneal infusion of catumaxomab
Trial: 31825525
Drug: Catumaxomab infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catumaxomab infusion
Trial: 28650782
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt containing Lactobacillus acidophilus ATCC 4356 and Bifidobacterium bifidum ATCC 29521 (200 g daily)
Trial: 28650782
Drug: Xylitol-containing chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol-containing chewing gums (two gums three times daily after each meal; total xylitol content: 5.58 g daily)
Trial: 19635898
Drug: Tafenoquine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200 mg weekly for 6 months
Trial: 31087729
Drug: Single-use negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-use negative pressure wound therapy (s-NPWT)
Trial: 31087729
Drug: Traditional negative
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional negative pressure wound therapy (t-NPWT)
Trial: 30266270
Drug: Probiotic Lactobacillus
RxNorm normalized name: Probiotic Lactobacillus Acidophilus Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Lactobacillus plantarum P8 (10 log CFU daily)
Trial: 28470492
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (30 mL for 90 days)
Trial: 28470492
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (30 mL for 90 days)
Trial: 28470492
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (30 mL for 90 days)
Trial: 12917744
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g caffeine
Trial: 9443520
Drug: Diphenhydramine 50
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 50 mg, p.o.
Trial: 9443520
Drug: Cyclobenzaprine 5
RxNorm normalized name: cyclobenzaprine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 5 mg, p.o.
Trial: 8440100
Drug: Continuous modes
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous modes of renal replacement therapy (CAVH/CAVHD)
Trial: 27650406
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 20‐70 mg/day, n=25
Trial: 24018777
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment at 1-month interval
Trial: 24018777
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser treatment at 3-month interval
Trial: 24018777
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment intervals (1-month and 3-month)
Trial: 16809072
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as allocated (specific intervention details not available)
Trial: 10996870
Drug: Regimen IR
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen IR (isoniazid 300 mg daily and rifampin 600 mg daily)
Trial: 10996870
Drug: Regimen I
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen I (isoniazid 300 mg daily for 12 months)
Trial: 28535785
Drug: Targeted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted medication therapy management (MTM) intervention
Trial: 8419602
Drug: Nebulized racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized racemic epinephrine, 0.1 ml/kg
Trial: 8419602
Drug: Nebulized salbutamol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol, 0.03 ml/kg
Trial: 20157180
Drug: Ocrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 200 mg/m2 (n=15)
Trial: 20157180
Drug: Ocrelizumab 375
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 375 mg/m2 (n=16)
Trial: 20157180
Drug: Ocrelizumab 375
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 375 mg/m2 first dose, then 750 mg/m2 (n=16)
Trial: 16006914
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg trospium chloride twice daily
Trial: 11952288
Drug: Intracutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injections of 100 units of Botulinum toxin A (BTXA) on the more severely affected hand
Trial: 8636336
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (various doses)
Trial: 8636336
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (optimal dose)
Trial: 10646895
Drug: L-carnitine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine treatment
Trial: 24614759
Drug: F-genotype attenuated
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-genotype attenuated mumps vaccine A (3.5 ± 0.25 logCCID50)
Trial: 24614759
Drug: F-genotype attenuated
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-genotype attenuated mumps vaccine B (4.25 ± 0.25 logCCID50)
Trial: 24614759
Drug: F-genotype attenuated
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-genotype attenuated mumps vaccine C (5.0 ± 0.25 logCCID50)
Trial: 24614759
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (licensed A-genotype vaccine S79 strain)
Trial: 20216563
Drug: Food plus
RxNorm normalized name: Cyclinex-1 Medical Food Plus Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food plus micronutrient capsule (MN) containing 15 mg zinc/day
Trial: 20216563
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement
Trial: 18381791
Drug: Fulvestrant (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (250 mg intramuscularly for 12 months)
Trial: 12407863
Drug: Proposed treatment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed treatment scheme including clopidogrel and abciximab
Trial: 29044764
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic BP target of <120 mmHg)
Trial: 29512468
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic BP target of <120 mmHg) with low baseline SBP (<150 mmHg)
Trial: 29044764
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic BP target of <140 mmHg)
Trial: 29042830
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg A-GPC
Trial: 29042830
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg A-GPC
Trial: 29042830
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Caffeine
Trial: 24492985
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM)/Amlodipine besylate (AM)/Hydrochlorothiazide (HCTZ) 40/10/25 mg
Trial: 22806822
Drug: Bupropion 100-150
RxNorm normalized name: bupropion hydrochloride 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 100-150 mg/day (100 mg/day for <30 kg and 150 mg/day for >30 kg)
Trial: 22806822
Drug: Methylphenidate 20-30
RxNorm normalized name: methylphenidate hydrochloride 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 20-30 mg/day
Trial: 9783884
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no flow modulator)
Trial: 2648763
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution with sodium concentration of 35 mmol/l and dextrose of 200 mmol/l
Trial: 2648763
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution with sodium concentration of 50 mmol/l and dextrose of 111 mmol/l
Trial: 2648763
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution with sodium concentration of 90 mmol/l and dextrose of 110 mmol/l
Trial: 27807039
Drug: Interviewer-administered Automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered Automated Multiple-Pass Method (AMPM) recall
Trial: 10948025
Drug: Homoeopathy (30c
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homoeopathy (30c preparation of principal inhalant allergen)
Trial: 26819104
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with intravenous rehydration
Trial: 24516621
Drug: Diet (D)
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet (D) treatment
Trial: 24516621
Drug: Exercise (E)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise (E) treatment
Trial: 21471562
Drug: ChemoEd intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ChemoEd intervention (DVD, question-prompt list, self-care information, education consultation ≥24 h before first treatment, telephone follow-up 48 h after first treatment, face-to-face review immediately before second treatment)
Trial: 2466846
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III and low-dose heparin
Trial: 2466846
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III and low-dose heparin (in cemented prosthesis group)
Trial: 20203546
Drug: lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 1.5 mg/kg and esmolol 1.0 mg/kg
Trial: 11960947
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1,500 mg/day)
Trial: 9534832
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg daily) for 1 week
Trial: 9534832
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg daily) for 3 weeks